AVCN.F Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.53 |
| 52 Week Low | CA$0.17 |
| Beta | 1.43 |
| 11 Month Change | -3.74% |
| 3 Month Change | -32.53% |
| 1 Year Change | -26.33% |
| 33 Year Change | -60.47% |
| 5 Year Change | -80.46% |
| Change since IPO | -92.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVCN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 13.7% | 4.2% | 2.0% |
| 1Y | -26.3% | 13.7% | 32.4% |
Return vs Industry: AVCN.F underperformed the US Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: AVCN.F underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| AVCN.F volatility | |
|---|---|
| AVCN.F Average Weekly Movement | 21.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVCN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AVCN.F's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Avicanna Inc. Fundamentals Summary
| AVCN.F fundamental statistics | |
|---|---|
| Market cap | US$21.81m |
| Earnings (TTM) | -US$4.83m |
| Revenue (TTM) | US$17.70m |
1.2x
P/S Ratio-4.4x
P/E RatioIs AVCN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCN.F income statement (TTM) | |
|---|---|
| Revenue | CA$24.90m |
| Cost of Revenue | CA$13.73m |
| Gross Profit | CA$11.17m |
| Other Expenses | CA$17.97m |
| Earnings | -CA$6.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 44.86% |
| Net Profit Margin | -27.32% |
| Debt/Equity Ratio | 0.9% |
How did AVCN.F perform over the long term?
See historical performance and comparison